Drug
Rezvilutamide clinical trials
Also written SHR3680.
- studies test it
- 22
- open now
- 9
- in phase 3
- 4
- first study started
- 2016
Keep track of what changes. Save the rezvilutamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
22 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 3 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 11
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 9
Jiangsu HengRui Medicine Co., Ltd. (12) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · Fudan University (2) · Atridia Pty Ltd. (1) · Fujian Medical University Union Hospital (1) · Jianbin Bi (1) · Peking University First Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Fluzoparib (3) · Leuprolide (2) · Abiraterone (2) · Trastuzumab rezetecan (1) · Tizetatug rezetecan (1) · Digoxin (1) · Rosuvastatin (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses rezvilutamide is read from its arms, and is right about nine times in ten.
Testing it · 22
- Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical ProstatectomyRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07711314Written as Rezvilutamide Tablets
- A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07241416Written as Rezvilutamide Tablets
- Rezvilutamide for High-Risk Prostate Cancer After SurgeryNot yet recruitingNot applicableFujian Medical University Union HospitalNCT07444983Written as Rezvilutamide and Leuprorelin
- Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct CarcinomaRecruitingPhase 2Peking University First HospitalNCT06348264Written as Rezvilutamide
- Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06305832Written as Rezvilutamide
- Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate CancerNot yet recruitingPhase 2Jianbin BiNCT06134271Written as Rezvilutamide
- Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPCRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05956639Written as 6-month course of antiandrogen drugs
- A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer SubjectsRecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05607693Written as SHR3680 tablets
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05406999Written as Rezvilutamide
- Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin HydrochlorideCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04621669Written as SHR3680
- A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical ProstatectomyTerminatedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05009290Written as SHR3680
- A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingActive, not recruitingPhase 2Fudan UniversityNCT05924256Written as SHR 3680 + leuprolide
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCTerminatedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04102124Written as SHR3680
- The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and OmeprazoleCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04676035Written as Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy ParticipantsStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04631549Written as SHR3680
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownPhase 2Fudan UniversityNCT04355858Written as SHR3680
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03520478Written as SHR3680
- A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04603833Written as SHR3680+Docetaxel
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCTerminatedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03741712Written as SHR3680
- Drug-drug Interaction of SHR3680 With Repaglinide and BupropionStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04664725Written as Repaglinide, Bupropion and SHR3680
See all 22 studies that test rezvilutamide →
Given in every arm · 5 — rezvilutamide is usual care beside what is tested
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07407283Written as Rezvilutamide
- Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate CancerNot yet recruitingPhase 2Fudan UniversityNCT07490210Written as Rezvilutamide + ADT
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as SHR3680 Tablet
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06387056Written as Rezvilutamide
- Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05753566Written as Rezvilutamide
As the comparator · 1 — what is tested is compared with rezvilutamide
Codes
What other systems call rezvilutamide · ClinicalTrials.gg INT015360
- UNII (FDA) 70FJN2AW22REZVILUTAMIDEConfirmed FDA, Wikidata
- Wikidata Q101063961rezvilutamideConfirmed FDA, Wikidata
- NCI Thesaurus C175852RezvilutamideOne source FDA
- DrugBank DB19133One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 70FJN2AW22 | REZVILUTAMIDE | Confirmed FDA, Wikidata |
| Wikidata | Q101063961 | rezvilutamide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175852 | Rezvilutamide | One source FDA |
| DrugBank | DB19133 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.